FDA Advisory Committee recommends belantamab mafodotin to treat relapsed or refractory multiple myeloma.- GSK
GlaxoSmithKline announced the FDA Oncologic Drugs Advisory Committee (ODAC) voted 12-0 in favour of the demonstrated benefit of monotherapy treatment with belantamab mafodotin outweighing the risks for patients… read more.